Patents by Inventor Bert Lynn

Bert Lynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOBINALINE N-OXIDES AS POSITIVE ALLOSTERIC MODULATORS OF THE DOPAMINE TRANSPORTER WITH POTENTIAL VALUE IN THE TREATMENT OF SUBSTANCE ABUSE DISORDERS
    Publication number: 20220401437
    Abstract: The presently-disclosed subject matter describes Lobinaline N-oxides as modulators of the dopamine transporter. The presently-disclosed subject matter further describes to Lobinaline N-oxides as modulators of the nicotinic acetylcholine receptors. Also described herein are methods for treating substance abuse disorders comprising administering Lobinaline N-oxides to a subject in need thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: December 22, 2022
    Inventors: John M. Littleton, Bert Lynn, Dennis T. Rogers, Greg Gerhardt
  • Treatment of MCI and Alzheimer's disease
    Patent number: 9968574
    Abstract: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD-L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 15, 2018
    Assignee: The University of Kentucky Research Foundation
    Inventors: Mark Lovell, Bert Lynn
  • TREATMENT OF MCI AND ALZHEIMER'S DISEASE
    Publication number: 20110118299
    Abstract: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD-L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.
    Type: Application
    Filed: November 18, 2010
    Publication date: May 19, 2011
    Applicant: The University of Kentucky Research Foundation
    Inventors: Mark Lovell, Bert Lynn
  • TREATMENT OF MCI AND ALZHEIMER'S DISEASE
    Publication number: 20100292281
    Abstract: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof.
    Type: Application
    Filed: May 13, 2010
    Publication date: November 18, 2010
    Applicant: The University of Kentucky Research Foundation
    Inventors: Mark Lovell, Bert Lynn